Can a Private Company Drag the NHS Toward Prevention?

Key Takeaways

• NHS prevention budget cut 28% in real terms over ten years
• Neko’s vertical‑integrated model sells £299 scans (~$380) directly to consumers
• Year‑two data shows 6.4% scans with important findings
• Consumer‑pull strategy mirrors Spotify’s disruptive product model
• Transparent reporting differentiates Neko from many health‑tech peers

Pulse Analysis

The United Kingdom’s National Health Service has repeatedly been warned that its prevention budget is eroding, with five major reviews over 23 years flagging the same crisis. Treasury analyses by Derek Wanless in 2002 and subsequent reports from Lord Darzi and the 2025 Ten‑Year Health Plan all point to a 28 % real‑terms decline in preventive spending, while acute care costs surge. This chronic under‑investment has left the NHS vulnerable, prompting policymakers to search for alternatives that can deliver measurable health gains without further draining public coffers.

Enter Neko, a private health‑tech firm that proposes a consumer‑pull solution. Drawing on analogies to Spotify’s disruption of music piracy and the market‑driven adoption of electric cars, CEO Hjalmar Nilsonne argues that prevention will only thrive if a product is compelling enough for individuals to pay for it themselves. By vertically integrating hardware, AI analytics, clinics, and follow‑up services, Neko can offer a £299 (≈$380) whole‑body scan that remains financially viable. The company’s publicly released data shows that 6.4 % of 4,362 scans in 2024 identified important health issues, while 81 % required no further action, suggesting a low false‑positive rate and a clear pathway for users to act on findings.

If Neko’s model proves scalable, it could pressure the NHS to collaborate with private innovators, redefining how preventive care is funded and delivered. Such partnerships might bring advanced diagnostics into mainstream use, reduce long‑term treatment costs, and shift the health system from reactive to proactive. However, challenges remain: regulatory scrutiny, data privacy, and ensuring equitable access across socioeconomic groups. The success of this consumer‑driven approach will hinge on demonstrable health outcomes, cost‑effectiveness, and the ability to integrate seamlessly with existing NHS pathways, potentially setting a new precedent for public‑private collaboration in preventive health.